T40.722 Poisoning by synthetic cannabinoids, intentional self-harm

Name of the Condition

• Common name: Intentional self-harm from synthetic cannabinoids
• Medical terms: Intentional self-poisoning by synthetic cannabinoids

Summary

This ICD code applies to intentional self-harm involving synthetic cannabinoids, where exposure is deliberate and aimed at causing harm. It covers scenarios where individuals intentionally ingest, inhale, or otherwise use synthetic cannabinoids to self-injure, leading to toxic effects requiring medical intervention.

Causes

Intentional self-harm typically results from deliberate overdose or misuse of synthetic cannabinoid products. This may involve consuming excessive amounts, combining with other substances, or using methods intended to maximize toxicity. Underlying factors often include mental health conditions, substance use disorders, or acute distress.

Risk Factors

• History of suicidal ideation or prior self-harm attempts
• Co-occurring mental health disorders (e.g., depression, anxiety)
• Substance use disorders involving synthetic cannabinoids or other drugs
• Access to synthetic cannabinoid products
• Acute psychosocial stressors or crises
• Lack of social support or isolation

Symptoms

• Severe agitation, anxiety, or paranoia
• Hallucinations or altered perception
• Nausea and vomiting
• Increased heart rate or palpitations
• Seizures or convulsions
• Loss of consciousness
• Respiratory distress or failure
• Hypotension or hypertension

Diagnosis

Diagnosis involves a clinical evaluation, detailed history of intentional exposure, and toxicology screens to confirm synthetic cannabinoid presence. Healthcare providers assess the severity of symptoms, mental status, and potential co-ingestants. Documentation of intent is critical for accurate coding.

Treatment Options

Treatment focuses on stabilizing the patient, managing symptoms, and addressing underlying causes. Interventions may include airway support, cardiovascular monitoring, anticonvulsants, and psychiatric evaluation. Supportive care, such as hydration and sedation, is often necessary. Long-term management may involve mental health services and substance use treatment.

Prognosis and Follow-Up

Prognosis depends on the severity of exposure, timely intervention, and underlying mental health status. Recovery may be complicated by residual psychiatric symptoms or substance use issues. Follow-up care typically includes psychiatric assessment, therapy, and monitoring for recurrence. Discharge planning should address safety and support systems.

Complications

• Respiratory failure or arrest
• Cardiovascular instability (e.g., arrhythmias, hypotension)
• Seizures or status epilepticus
• Rhabdomyolysis or renal failure
• Psychiatric decompensation (e.g., psychosis, depression)
• Long-term cognitive or neurological deficits

Lifestyle & Prevention

• Secure storage of synthetic cannabinoid products to prevent access
• Education on risks and safe disposal of unused substances
• Mental health support and crisis intervention resources
• Substance use treatment programs for at-risk individuals
• Regular monitoring of high-risk patients

When to Seek Professional Help

Seek immediate medical attention if self-harm with synthetic cannabinoids is suspected or confirmed. Signs requiring urgent care include altered mental status, seizures, difficulty breathing, or loss of consciousness. Prompt evaluation is critical to prevent life-threatening complications.

Tips for Medical Coders

Document the intent (intentional self-harm) clearly in the medical record, as this distinguishes the code from accidental or therapeutic exposures. Include details of the substance, route of exposure, and clinical findings to support coding accuracy. Ensure alignment with clinical documentation standards for self-harm and poisoning scenarios.